If you do not receive a confirmation email within 48 hours, please check back again on this page to see the status of your verification. All other documents will not be accepted.ĭocument verification takes about one working day to process. Please provide official documentation attesting Neuropsychologist title or relevant fellowship. Exempted from mandatory certification: Neuropsychologists and clinicians who have completed 1-year post-doc cognitive fellowship.Ĭompletion of the 1-hour online training and certification module is required for the vast majority of medical doctors, nurses, occupational therapists, speech-language pathologists, psychologists, and other health professionals currently using –or planning to use-MoCA in clinical practice or research. These effects may enhance energy metabolism in the brain, as well as contribute to the beneficial effects seen in patients with diabetic complications (e.g. In addition, Actovegin also has multiple metabolic effects, including improved oxygen utilisation and uptake, enhanced cellular energy metabolism and increased glucose uptake. This modulation of the NF-κB pathway may in part explain the neuroprotective and anti-apoptotic effects of Actovegin. Recently, Actovegin has also been shown to activate the in vitro expression of NF-κB, a transcription factor that is believed to have neuroprotective properties. It has been reported to increase the number of neuronal cells and synaptic connections and to reduce apoptosis in a dose-dependent manner when added to freshly cultured primary rat neurons in vitro. ARTEMIDA should provide important insights into the use of a novel drug therapy for PSCI.Īs a result of its large number of bioactive constituents, Actovegin affects numerous biochemical pathways and has pleiotropic neuroprotective and metabolic effects. Conclusion: There is a clear need for effective treatments for PSCI. Secondary outcomes include: Montreal Cognitive Assessment dementia diagnosis (ICD-10) National Institutes of Health Stroke Scale Barthel Index EQ-5D Beck Depression Inventory, version II, and safety. The primary study endpoint is change from baseline in the Alzheimer's Disease Assessment Scale, cognitive subscale, extended version. Patients will be followed up for a further 6 months, during which time they will be treated in accordance with standard clinical practice. The study consists of a baseline screening (≤7 days after stroke), after which eligible patients are randomised to Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally) or placebo for a 6-month double-blind treatment period. Design: ARTEMIDA is a 12-month, multicentre trial in patients (planned a total of 500, now recruited) with cognitive impairment following ischaemic stroke. The ongoing ARTEMIDA study will evaluate the efficacy and safety of Actovegin for the symptomatic treatment of post-stroke cognitive impairment (PSCI) and will explore whether Actovegin has any disease-modifying effect by assessing whether any changes are sustained after treatment. Background: No drug treatment to date has shown convincing clinical evidence of restoring cognitive function or preventing further decline after stroke.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |